New drug combo tested in fight against advanced liver cancer

NCT ID NCT02519348

Ongoing Disease control Sponsor: MedImmune LLC Source: ClinicalTrials.gov ↗

Summary

This study tested several immunotherapy drugs, alone and in combination, for people with advanced liver cancer that had stopped responding to standard treatment. The main goals were to see if the treatments were safe and if they could help control the cancer. Researchers enrolled 433 participants to receive different dosing schedules of the drugs durvalumab and tremelimumab, or a combination with bevacizumab.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Phoenix, Arizona, 85054, United States
Research Site

San Francisco, California, 94158, United States
Research Site

New Haven, Connecticut, 06510, United States
Research Site

Jacksonville, Florida, 32224, United States
Research Site

Tampa, Florida, 33612, United States
Research Site

Indianapolis, Indiana, 46202, United States
Research Site

Boston, Massachusetts, 02114, United States
Research Site

New York, New York, 10065, United States
Research Site

Stony Brook, New York, 11794, United States
Research Site

Durham, North Carolina, 27705, United States
Research Site

Portland, Oregon, 97213, United States
Research Site

Philadelphia, Pennsylvania, 19107, United States
Research Site

Philadelphia, Pennsylvania, 19111, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Dallas, Texas, 75390, United States
Research Site

Seattle, Washington, 98109, United States
Research Site

Hangzhou, 310016, China
Research Site

Nanjing, 210002, China
Research Site

Shanghai, 200032, China
Research Site

Hong Kong, Hong Kong
Research Site

Shatin, Hong Kong
Research Site

Benevento, 82100, Italy
Research Site

Milan, 20133, Italy
Research Site

Roma, 00168, Italy
Research Site

Chūōku, 104-0045, Japan
Research Site

Kashiwa, 277-8577, Japan
Research Site

Osakasayama-shi, 589-8511, Japan
Research Site

Bukit Merah, 169610, Singapore
Research Site

Singapore, 119074, Singapore
Research Site

Singapore, 308433, Singapore
Research Site

Busan, 49241, South Korea
Research Site

Junggu, 41944, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06273, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Barcelona, 08035, Spain
Research Site

Barcelona, 08036, Spain
Research Site

Córdoba, 14004, Spain
Research Site

Pamplona, 31008, Spain
Research Site

Kaohsiung City, 83301, Taiwan
Research Site

Taipei, 100, Taiwan
Research Site

Taoyuan, 333, Taiwan

Conditions

Explore the condition pages connected to this study.

HEPATOCELLULAR CARCINOMA